Heron Therapeutics (Heron Therapeutics) Cash, Cash Equivalents, Marketable Securities : $80.4 Mil (As of Dec. 2023)

View and export this data going back to 1987. Start your Free Trial

What is Heron Therapeutics Cash, Cash Equivalents, Marketable Securities?

Heron Therapeutics's quarterly cash, cash equivalents, marketable securities increased from Jun. 2023 ($33.24 Mil) to Sep. 2023 ($77.41 Mil) and increased from Sep. 2023 ($77.41 Mil) to Dec. 2023 ($80.41 Mil).

Heron Therapeutics's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($157.58 Mil) to Dec. 2022 ($84.85 Mil) and declined from Dec. 2022 ($84.85 Mil) to Dec. 2023 ($80.41 Mil).

Heron Therapeutics Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Heron Therapeutics's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heron Therapeutics Cash, Cash Equivalents, Marketable Securities Chart

Heron Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

390.97

208.49

157.58

84.85

80.41

Heron Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															84.85	60.02	33.24	77.41	80.41

Heron Therapeutics Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Heron Therapeutics (NAS:HRTX) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Heron Therapeutics Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Heron Therapeutics's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Heron Therapeutics (Heron Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heron Therapeutics Inc (NAS:HRTX) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

AXD2:Germany AXD2:Germany

Address

4242 Campus Point Court, Suite 200, San Diego, CA, USA, 92121

Website

https://www.herontx.com

Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of SUSTOL, ZYNRELEF, and CINVANTI. Its pipeline product is HTX-011.

Executives

William P Forbes	officer: EVP, Chief Development Officer	C/O SALIX PHARMACEUTICALS, LTD., 8510 COLONNADE CENTER DRIVE, RALEIGH NC 27615
Adam Morgan	other: See Footnote 2	1055B POWERS PLACE, ALPHARETTA GA 30009
Ira Duarte	officer: EVP, Chief Financial Officer	1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Craig A Collard	director	C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Kevin Kotler	director	C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Velan Capital Master Fund Lp	other: See Footnote 2	1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Management Llc	other: See Footnote 2	1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Holdings Llc	other: See Footnote 2	1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Investment Management Lp	other: See Footnote 2	1055B POWERS PLACE, ALPHARETTA GA 30009
David Efraim Rosen	other: See Footnote 1	155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Rubric Capital Management Lp	other: See Footnote 1	155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
Balaji Venkataraman	other: See Footnote 2	FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Kimberly Manhard	director	C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121
Craig A Johnson	director	C/O PURE BIOSCIENCE, 1725 GILLESPIE WAY, EL CAJON CA 92020
Waage Christian	director	RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121